StockWatch
·
Filing
Q2

Shree Ganesh Remedies Ltd

SGRLFY2607 Nov 2025
Revenue+22.9%
Net Profit+43.9%
OPM31.73%

P&L

Quarterly Consolidated

Revenue
+22.9%30.32
Expenditure
+17.2%24.29
Net Profit
+43.9%4.96
NPM 15.98%+17.5%EPS ₹3.86+44.0%

vs Q1 FY26

Shree Ganesh Remedies Limited Reports Q2 & H1FY26 Results with Sequential Growth and Resilient Profitability

07 Nov 2025 · 7 Nov 2025, 08:13 pm

Summary

Shree Ganesh Remedies Limited, a leading player in the chemical manufacturing industry, reported its financial results for Q2 & H1FY26. The company delivered sequential growth in Q2FY26, driven by higher volumes and steady execution across key client projects. Despite muted realisations and the impact of higher depreciation and finance costs, profitability remained resilient. The company is confident of sustaining its EBITDA margins in the range of 24-26% over the long term. Operationally, the new pilot facility is in the final stages of commissioning, with operations scheduled to commence in Q4FY26. The company is also actively evaluating new opportunities in European and Japanese markets.

Key Highlights

  1. 1

    Revenue for Q2FY26 is 30.32 Cr, down 6% YoY

  2. 2

    PAT for Q2FY26 is 4.93 Cr, down 23% YoY

  3. 3

    Revenue from Pharma Intermediates in Q2FY26 is 17.30 Cr

  4. 4

    Revenue from Exports in Q2FY26 is not explicitly mentioned

  5. 5

    EBITDA for Q2FY26 is 9.62 Cr, down 15% YoY

  6. 6

    EBITDA margins for Q2FY26 are 31.7%, down 325 BPS YoY

  7. 7

    Revenue from Speciality Chemicals in Q2FY26 is 12.79 Cr

  8. 8

    Revenue from Domestic Sales in Q2FY26 is not explicitly mentioned

  9. 9

    Revenue for H1FY26 is 54.98 Cr, down 4% YoY

  10. 10

    PAT for H1FY26 is 8.37 Cr, down 24% YoY

  11. 11

    Revenue from Pharma Intermediates in H1FY26 is 28.37 Cr

  12. 12

    Revenue from Exports in H1FY26 is not explicitly mentioned

  13. 13

    EBITDA for H1FY26 is 16.92 Cr, down 13% YoY

  14. 14

    EBITDA margins for H1FY26 are 30.8%, down 326 BPS YoY

  15. 15

    Revenue from Speciality Chemicals in H1FY26 is 26.26 Cr

  16. 16

    Revenue from Domestic Sales in H1FY26 is not explicitly mentioned

Management Comments

M

Mr. Gunjan Kothia

In line with our expectations, SGRL delivered sequential growth in Q2FY26, reflecting the company’s historically stronger performance in this quarter. The quarter-on- quarter improvement was driven by higher volumes and steady execution across key client projects. On a year-on- year basis, however, sales remained subdued due to lower realisations in the domestic market and softened demand across Europe. As previously guided, our margins continued to moderate with the repricing of contracts within the CRAMS business. We remain focused on optimising our product mix to sustain profitability amid these evolving dynamics. Despite muted realisations and the impact of higher depreciation and finance costs arising from recent capital investments, our profitability remained resilient. We continue to remain confident of sustaining our EBITDA margins in the range of 24-26% over the long term. Operationally, we have made substantial progress on the new pilot facility, which has now reached the final stages of commissioning. Completion is expected in Q3FY26, with operations scheduled to commence in Q4FY26. Work on Block 7 is progressing as planned, with the plant expected to be operational and begin commercial production in H2FY27. The newly commissioned Block 8 also showed encouraging trends with rising capacity utilisation through the quarter. We aim to achieve 50-60% utilisation by the end of the current financial year. On the business development front, we received approval from a European client for a new agrochemical project, with commercial orders scheduled to begin by Q4FY27. In Europe, we also secured a significant engagement with a leading pharmaceutical company. Progress with our Japanese client on the specialty chemicals project continues positively, and we expect to receive final project approvals by mid-2026. Additionally, we are actively evaluating new opportunities in European and Japanese market. Overall, we continue to strengthen our infrastructure and innovation capabilities. As guided earlier, FY26 remains a year of consolidation and capability-building, laying a strong foundation for scale-up and accelerated growth in the years ahead.

Informational and educational content only. Not investment advice.